494 related articles for article (PubMed ID: 31624029)
41. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection.
Nathwani D; Cornely OA; Van Engen AK; Odufowora-Sita O; Retsa P; Odeyemi IA
J Antimicrob Chemother; 2014 Nov; 69(11):2901-12. PubMed ID: 25096079
[TBL] [Abstract][Full Text] [Related]
42. Reduction in Clostridium difficile environmental contamination by hospitalized patients treated with fidaxomicin.
Biswas JS; Patel A; Otter JA; Wade P; Newsholme W; van Kleef E; Goldenberg SD
J Hosp Infect; 2015 Jul; 90(3):267-70. PubMed ID: 25728208
[TBL] [Abstract][Full Text] [Related]
43. The use of fidaxomicin for treatment of relapsed Clostridium difficile infections in patients with cancer.
Esmaily-Fard A; Tverdek FP; Crowther DM; Ghantoji SS; Adachi JA; Chemaly RF
Pharmacotherapy; 2014 Nov; 34(11):1220-5. PubMed ID: 25164587
[TBL] [Abstract][Full Text] [Related]
44. Comparative efficacy of treatments for Clostridium difficile infection: a systematic review and network meta-analysis.
Beinortas T; Burr NE; Wilcox MH; Subramanian V
Lancet Infect Dis; 2018 Sep; 18(9):1035-1044. PubMed ID: 30025913
[TBL] [Abstract][Full Text] [Related]
45. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections.
Lancaster JW; Matthews SJ
Clin Ther; 2012 Jan; 34(1):1-13. PubMed ID: 22284993
[TBL] [Abstract][Full Text] [Related]
46. Clinical Efficacy of Fidaxomicin and Oral Metronidazole for Treating
Mori N; Hirai J; Ohashi W; Asai N; Shibata Y; Mikamo H
Antibiotics (Basel); 2023 Aug; 12(8):. PubMed ID: 37627743
[No Abstract] [Full Text] [Related]
47. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection: EXTEND study subgroup analyses.
Cornely OA; Vehreschild MJGT; Adomakoh N; Georgopali A; Karas A; Kazeem G; Guery B
Eur J Clin Microbiol Infect Dis; 2019 Jun; 38(6):1187-1194. PubMed ID: 30911926
[TBL] [Abstract][Full Text] [Related]
48. An Open-Label, Randomized Trial Comparing Fidaxomicin With Oral Vancomycin for the Treatment of Clostridioides difficile Infection in Hospitalized Patients Receiving Concomitant Antibiotics for Concurrent Infections.
Rao K; Zhao Q; Bell J; Krishnan J; Henig O; Daniel J; Sawaya K; Albin O; Mills JP; Petty LA; Gregg K; Kaul D; Malani AN; Pogue J; Kaye KS
Clin Infect Dis; 2024 Feb; 78(2):277-282. PubMed ID: 37797310
[TBL] [Abstract][Full Text] [Related]
49. Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain.
Rubio-Terrés C; Cobo Reinoso J; Grau Cerrato S; Mensa Pueyo J; Salavert Lletí M; Toledo A; Anguita P; Rubio-Rodríguez D; Watt M; Gani R
Eur J Clin Microbiol Infect Dis; 2015 Nov; 34(11):2213-23. PubMed ID: 26407619
[TBL] [Abstract][Full Text] [Related]
50. Efficacy and Safety of Metronidazole Monotherapy versus Vancomycin Monotherapy or Combination Therapy in Patients with Clostridium difficile Infection: A Systematic Review and Meta-Analysis.
Li R; Lu L; Lin Y; Wang M; Liu X
PLoS One; 2015; 10(10):e0137252. PubMed ID: 26444424
[TBL] [Abstract][Full Text] [Related]
51. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
Louie TJ; Cannon K; Byrne B; Emery J; Ward L; Eyben M; Krulicki W
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S132-42. PubMed ID: 22752862
[TBL] [Abstract][Full Text] [Related]
52. Fidaxomicin in the treatment of Clostridium difficile infection in oncohematology patients.
Martín Rizo L; Malpartida Flores M; Fernández Lisón LC
Med Clin (Barc); 2019 Oct; 153(7):298-299. PubMed ID: 30337114
[No Abstract] [Full Text] [Related]
53. Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE).
Wolf J; Kalocsai K; Fortuny C; Lazar S; Bosis S; Korczowski B; Petit A; Bradford D; Croos-Dabrera R; Incera E; Melis J; van Maanen R
Clin Infect Dis; 2020 Dec; 71(10):2581-2588. PubMed ID: 31773143
[TBL] [Abstract][Full Text] [Related]
54. Does Addition of Intravenous Metronidazole to Oral Vancomycin Improve Outcomes in Clostridioides difficile Infection?
Wang Y; Schluger A; Li J; Gomez-Simmonds A; Salmasian H; Freedberg DE
Clin Infect Dis; 2020 Dec; 71(9):2414-2420. PubMed ID: 31714955
[TBL] [Abstract][Full Text] [Related]
55. Fidaxomicin for the treatment of
Skinner AM; Scardina T; Kociolek LK
Future Microbiol; 2020 Jul; 15(11):967-979. PubMed ID: 32715754
[TBL] [Abstract][Full Text] [Related]
56. Cost-effectiveness of three different strategies for the treatment of first recurrent Clostridium difficile infection diagnosed in a community setting.
Lam SW; Neuner EA; Fraser TG; Delgado D; Chalfin DB
Infect Control Hosp Epidemiol; 2018 Aug; 39(8):924-930. PubMed ID: 29961435
[TBL] [Abstract][Full Text] [Related]
57. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.
Johnson S; Louie TJ; Gerding DN; Cornely OA; Chasan-Taber S; Fitts D; Gelone SP; Broom C; Davidson DM;
Clin Infect Dis; 2014 Aug; 59(3):345-54. PubMed ID: 24799326
[TBL] [Abstract][Full Text] [Related]
58. Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice.
Warren CA; van Opstal EJ; Riggins MS; Li Y; Moore JH; Kolling GL; Guerrant RL; Hoffman PS
Antimicrob Agents Chemother; 2013 Feb; 57(2):689-96. PubMed ID: 23147742
[TBL] [Abstract][Full Text] [Related]
59. Antibiotic Therapies for Clostridioides difficile Infection in Children.
Gonzales-Luna AJ; Carlson TJ; Garey KW
J Pediatric Infect Dis Soc; 2021 Nov; 10(Supplement_3):S52-S57. PubMed ID: 34791393
[TBL] [Abstract][Full Text] [Related]
60. Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection.
Chen J; Gong CL; Hitchcock MM; Holubar M; Deresinski S; Hay JW
Clin Microbiol Infect; 2021 Oct; 27(10):1448-1454. PubMed ID: 33878506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
